Between the Biotech Waves Episode 35: A Between the Biotech Waves Conversation with Mike Curtis, President & CEO of eGenesis
Welcome back to Between the Biotech Waves. I am sorry for the lack of episodes over the past few months, unfortunately life threw me a curve ball that I have been taking care of but now back and ready to go!
Today it gives me great pleasure to introduce Mike Curtis, President and CEO of eGenesis. You may recall seeing eGenesis on the front cover of the New York Times recently following the first successful xenotransplantation of a genetically modified porcine kidney. This followed years of work within eGenesis to develop porcine donors for human tissue transplant.
Mike has a 25 year plus history in biotech from Infinity to Cadent where he played a critical role in the merger of Ataxion Therapeutics with Luc to Catabasis where he led product development and regulatory affairs to his current role as CEO and President at eGenesis. Mike earned his Ph.D. in Cell and Molecular Biology from the State University of New York Upstate Medical University.
His story is fascinating. Please join me in welcoming Mike Curtis.